VC Lab is a venture capital accelerator that helps managers worldwide close on capital in under 6 months. It also offers training programs for accredited investors and aspiring professionals in the venture capital industry.

VC Lab

The Allstate Corporation is a leading insurance provider in the United States, offering a wide range of insurance products and financial services. The company is known for its auto, home, and life insurance policies, as well as its retirement and investment products.

Van Mays

Rajan Paul

Rick Coomer

David J Grich

Allstate Corporation

Banfield Pet Hospital provides veterinary care services and pet wellness plans. The company self-describes itself as offering quality pet care.

Banfield Pet Hospital

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and Fisogatinib, an orally available and potent inhibitor for the treatment of hepatocellular carcinoma. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered solid tumors, medullary thyroid carcinoma, and other solid tumors; BLU-701 and BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Metric
Company Name	VC Lab	Allstate Corporation	Banfield Pet Hospital	Blueprint Medicines Corporation
Symbol				BPMC
MSH ID	COM:GOVCLAB	COM:ALLSTATE	COM:BANFIELD	COM:BLUEPRINTMEDICINES
Market	PRIVATE	PRIVATE	PRIVATE	STOCKS
Sector	Financial Services & Finance	Financial Services & Finance	Healthcare & Health Services	Healthcare
Industry	Venture Capital	Insurance	Veterinary Services	Biotechnology
Country	US	US	US	US
Stage	Pre Seed
Employee Count		7.49K		645
Website	govclab.com	allstate.com	banfield.com	blueprintmedicines.com
LinkedIn		allstate-financial
Founders

Metric
Market Cap				7.26B
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue				249.38M
Revenue (LTM)
Revenue (NTM)
Gross Profit				224.92M
EBITDA				-474.61M
Operating Income				-486.28M
Net Income				-506.98M
EPS				-8.37
Diluted EPS				-8.37
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin				0.96
Operating Profit Margin				-0.98
EBITDA Margin				-1.90
Net Profit Margin				-0.57
Return on Equity				-0.85
Return on Assets				-0.17
Return on Capital Employed				-0.37

COM:GOVCLAB

VC Lab

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio				-8.39
P/B Ratio				22.98
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio				26.58
EV Multiple				-9.68

Metric
Days Sales Outstanding				69.65
Days Payables Outstanding				170.58
Days Inventory Outstanding				952.36
Operating Cycle				1.03K
Cash Conversion Cycle				878.40
Asset Turnover				0.30

Metric
Operating Cash Flow				-436.85M
Free Cash Flow				-452.91M
Cash Flow to Debt				-0.50
Operating Cash Flow/Sales				-0.92
Free Cash Flow Yield				-0.11

Metric
Cash & Equivalents				71.29M
Accounts Receivable				-7.65M
Inventory				21.22M
Goodwill
Debt to Capitalization				0.84
Debt to Assets				0.11
Current Ratio				4.09
Quick Ratio				3.65

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue				0.44
R&D to Revenue				2.08
SG&A to Revenue				0.51